On June 18, 2020, Sangamo Therapeutics, Inc. (“Sangamo”) and Adrian Woolfson, B.M., B.Ch., Ph.D. discussed the end of his employment as Sangamo’s Executive Vice President of Research and Development, and, in connection therewith, the Company and Dr. Woolfson agreed that Dr. Woolfson’s employment relationship with Sangamo will end as of June 24, 2020.